To the Editor The article by Hershman et al1 is based on Medicare claims—not actual medical record review and talking with patients. In 1983, I and 3 other American investigators collaborated with Fernand Labrie from Laval University using continuous androgen deprivation (CAD) composed of Eulexin (flutamide) plus the luteinizing hormone–releasing hormone (LHRH) agonist D-Trp6-LHRH (triptorelin pamoate [Trelstar]). In approximately 1989, the US Food and Drug Administration approved the “American counterparts” bicalutamide and leuprolide acetate. In about 1989, a few of my medical oncology colleagues and I began using intermittent androgen deprivation (IAD) but with a far different methodology2,3 than how IAD was administered in SWOG 9346.
Strum SB, Scholz MC. Adverse Health Effects of Intermittent vs Continuous Androgen Deprivation Therapy for Metastatic Prostate CancerRelating 33 Years of Patient Clinical Care. JAMA Oncol. 2016;2(5):686. doi:10.1001/jamaoncol.2016.0367